Human papillomavirus correlates of high grade cervical dysplasia among HIV-Infected women at a major treatment centre in Nigeria: a cross-sectional study.
Adult
Aged
CD4 Lymphocyte Count
Cohort Studies
Cross-Sectional Studies
Female
HIV Infections
/ complications
Humans
Mass Screening
/ methods
Middle Aged
Nigeria
/ epidemiology
Papillomaviridae
/ isolation & purification
Papillomavirus Infections
/ epidemiology
Prevalence
Uterine Cervical Dysplasia
/ diagnosis
HIV-positive women
Human papillomavirus
Nigeria
genotypes
premalignant lesions
uterine cervix
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
11
2018
accepted:
28
01
2019
entrez:
28
9
2019
pubmed:
29
9
2019
medline:
9
10
2019
Statut:
epublish
Résumé
Persistent high-risk HPV (hrHPV) infection is higher among women living with HIV/AIDS thus increasing their risk for cervical cancer. We evaluated the virological and immunological correlates of cervical dysplasia in HIV-infected women. A cohort of 220 consenting women attending the antiretroviral clinic of the Federal Medical Centre, Keffi, Nigeria was tested for cervical human papilloma virus (HPV) infection using PCR. The prevalent HPV genotypes were determined by DNA sequencing. CD4+T count and type specific HPV was correlated with cervical cytology. Descriptive and inferential statistical analysis of the data was done using the statistical package for social sciences (SPSS) version 20 (SPSS Inc, Illinois, USA) for analysis after validation. Overall HPV prevalence was 54.1% while the hrHPV prevalence was 35.9%. Premalignant and malignant lesions were observed among participants with CD4+T counts between 200-300/mm Risk stratification with HPV screening among HIV-infected women will help in early case management of cervical precancerous lesions.
Identifiants
pubmed: 31558924
doi: 10.11604/pamj.2019.33.125.17589
pii: PAMJ-33-125
pmc: PMC6754827
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Natl Cancer Inst. 1999 Feb 3;91(3):226-36
pubmed: 10037100
Sex Transm Infect. 1999 Apr;75(2):103-6
pubmed: 10448362
Br J Cancer. 2004 Feb 9;90(3):638-45
pubmed: 14760378
J Virol Methods. 2004 Dec 1;122(1):87-93
pubmed: 15488625
Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12
pubmed: 15867955
J Infect Dis. 2006 Aug 15;194(4):428-34
pubmed: 16845625
JAMA. 2007 Feb 28;297(8):813-9
pubmed: 17327523
Br J Biomed Sci. 2007;64(1):18-22
pubmed: 17444414
J Med Virol. 2007 Jun;79(6):758-65
pubmed: 17457908
Int J STD AIDS. 2008 Jan;19(1):37-41
pubmed: 18275645
BMC Cancer. 2009 Aug 07;9:275
pubmed: 19664216
Vaccine. 2010 Jul 12;28(31):4864-7
pubmed: 20566394
BMC Infect Dis. 2011 Dec 02;11:333
pubmed: 22136570
J Clin Virol. 2012 Jun;54(2):141-6
pubmed: 22437054
Asian Pac J Cancer Prev. 2012;13(1):91-6
pubmed: 22502720
AIDS Res Treat. 2012;2012:953743
pubmed: 22548156
Br J Cancer. 2012 Oct 23;107(9):1624-30
pubmed: 23033006
J Int AIDS Soc. 2013 Feb 14;16:18023
pubmed: 23406965
Open Virol J. 2013;7:19-27
pubmed: 23494633
Int J Womens Health. 2013 Aug 13;5:487-94
pubmed: 23976867
BMC Infect Dis. 2013 Nov 05;13:521
pubmed: 24192311
Front Oncol. 2014 Mar 14;4:48
pubmed: 24672770
BMC Public Health. 2014 Jun 27;14:656
pubmed: 24972674
J Transl Med. 2014 Nov 26;12:300
pubmed: 25424736
Ann N Y Acad Sci. 1989;567:58-68
pubmed: 2552893
Infect Agent Cancer. 2015 Oct 02;10:39
pubmed: 26435733
Lancet. 1998;351 Suppl 3:22-4
pubmed: 9652717